Cell line · CVCL_1465
NCI-H1373
Cancer cell line, Homo sapiens. Lung adenocarcinoma. 34 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. NCI-H1373. Cell lines, record CVCL_1465. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_1465
On this page
Cell line
As Cellosaurus gives it.
- Name
- NCI-H1373
- Accession
- CVCL_1465
- RRID
- RRID:CVCL_1465
- Synonyms
- H1373, H-1373, NCIH1373
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- 56Y
- Category
- Cancer cell line
- Diseases
- Lung adenocarcinoma (NCIt C3512)
- Derived from
- Lung (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2025-08-14
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers34
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Virtual Tumors Enable Prediction of Personalized Therapeutic Combinations for Non-Small Cell Lung Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Activity of Direct KRAS(G12C) Inhibitors in Preclinical Models of Pediatric Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Wild-type RAS signaling is an essential therapeutic target in RAS-mutated cancers. | Sci Signal | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SOS1 Inhibition Enhances the Efficacy of KRASG12C Inhibitors and Delays Resistance in Lung Adenocarcinoma. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non-Small Cell Lung Cancer Patient-Derived Tumor Organoids. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 34
See all 34 papersRelatives0
None in this release.
Cell banks3
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | CRL-5866 | ATCC | |
| AddexBio | C0016047/5012 | Cellosaurus | |
| KCLB | 91373 | KCLB |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1465
GET https://conductscience.org/api/cell-lines/v1/CVCL_1465/papers?page=2